Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies | 百济神州

⟵ Back to Search Results

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Beigene Study ID

BGB-3111_BGB-A317_Study_001

ClinicalTrials.gov ID

NCT02795182

Clinical Drug Trials ID

CTR20180193

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents